de Blank, P. M. K., Gross, A. M., Akshintala, S., Blakeley, J. O., Bollag, G., Cannon, A., Dombi, E., Fangusaro, J., Gelb, B. D., Hargrave, D., Kim, A., Klesse, L. J., Loh, M., Martin, S., Moertel, C., Packer, R., Payne, J. M., Rauen, K. A., Rios, J. J., Robison, N., Schorry, E. K., Shannon, K., Stevenson, D. A., Stieglitz, E., Ullrich, N. J., Walsh, K. S., Weiss, B. D., Wolters, P. L., Yohay, K., Yohe, M. E., Widemann, B. C., & Fisher, M. J. (2022). mEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-oncology, 24(11), 1845–1856. http://access.bl.uk/ark:/81055/vdc_100169532815.0x000023